SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Bjorn Nashan, Peter Schemmer, Felix Braun, Markus Dworak, Peter Wimmer, Hans Schlitt, Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial, Trials, 2015, 16, 1

    CrossRef

  2. 2
    M. Jiménez-Pérez, R. González Grande, F.J. Rando Muñoz, J. de la Cruz Lombardo, M.A. Muñoz Suárez, J.L. Fernández Aguilar, J.A. Pérez Daga, J. Santoyo-Santoyo, R. Manteca González, J.M. Rodrigo López, Everolimus Plus Mycophenolate Mofetil as Initial Immunosuppression in Liver Transplantation, Transplantation Proceedings, 2015, 47, 1, 90

    CrossRef

  3. 3
    Christophe Duvoux, Christian Toso, mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?, Transplantation Reviews, 2015, 29, 3, 168

    CrossRef

  4. 4
    Hallvard Holdaas, Luciano Potena, Faouzi Saliba, mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?, Transplantation Reviews, 2015, 29, 2, 93

    CrossRef

  5. 5
    Greg J. McKenna, Göran B.G. Klintmalm, Transplantation of the Liver, 2015,

    CrossRef

  6. 6
    Richard Ruiz, Allan D. Kirk, Transplantation of the Liver, 2015,

    CrossRef

  7. 7
    Daniel Nils Gotthardt, Helge Bruns, Karl Heinz Weiss, Peter Schemmer, Current strategies for immunosuppression following liver transplantation, Langenbeck's Archives of Surgery, 2014, 399, 8, 981

    CrossRef

  8. 8
    S. K. Asrani, R. H. Wiesner, J. F. Trotter, G. Klintmalm, E. Katz, E. Maller, J. Roberts, N. Kneteman, L. Teperman, J. J. Fung, J. M. Millis, De Novo Sirolimus and Reduced-Dose Tacrolimus Versus Standard-Dose Tacrolimus After Liver Transplantation: The 2000–2003 Phase II Prospective Randomized Trial, American Journal of Transplantation, 2014, 14, 2
  9. 9
    Lluís Castells, Carme Baliellas, Itxarone Bilbao, Carme Cantarell, Josep Maria Cruzado, Núria Esforzado, Juan Carlos García-Valdecasas, Laura Lladó, Antoni Rimola, Daniel Serón, Federico Oppenheimer, Detección precoz, prevención y manejo de la insuficiencia renal en el trasplante hepático, Gastroenterología y Hepatología, 2014, 37, 8, 480

    CrossRef

  10. 10
    M. Sterneck, G. M. Kaiser, N. Heyne, N. Richter, F. Rauchfuss, A. Pascher, P. Schemmer, L. Fischer, C. G. Klein, S. Nadalin, F. Lehner, U. Settmacher, P. Neuhaus, D. Gotthardt, M. Loss, S. Ladenburger, E. M. Paulus, M. Mertens, H. J. Schlitt, Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation, American Journal of Transplantation, 2014, 14, 3
  11. 11
    James F. Trotter, Luis Lizardo-Sanchez, Everolimus in liver transplantation, Current Opinion in Organ Transplantation, 2014, 19, 6, 578

    CrossRef

  12. 12
    Liya Su, Ngalei Tam, Ronghai Deng, Philip Chen, Haibo Li, Linwei Wu, Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis, International Urology and Nephrology, 2014, 46, 10, 2035

    CrossRef

  13. 13
    Εvangelos Cholongitas, Ioannis Goulis, Eleni Theocharidou, Nikolaos Antoniadis, Ioannis Fouzas, Dimitrios Giakoustidis, George Imvrios, Olga Giouleme, Vasilios Papanikolaou, Evangelos Akriviadis, Themistoklis Vasiliadis, Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience, Hepatology International, 2014, 8, 1, 137

    CrossRef

  14. 14
    Gabriele Catalano, Paolo De Simone, Alessandro Mazzoni, Davide Ghinolfi, Laura Coletti, Franco Filipponi, Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome, Transplant International, 2014, 27, 9
  15. 15
    L.-B. Jeng, A. Thorat, Y.-W. Hsieh, H.-R. Yang, C.-C. Yeh, T.-H. Chen, S.-C. Hsu, C.-H. Hsu, Experience of Using Everolimus in the Early Stage of Living Donor Liver Transplantation, Transplantation Proceedings, 2014, 46, 3, 744

    CrossRef

  16. 16
    Federico G. Villamil, Adrian C. Gadano, Fernanda Zingale, Roberto Perez, Octavio Gil, Silvina Yantorno, Ricardo Mastai, Fernando O. Cairo, Alcira B. Otero, Gaohong Dong, Patricia Lopez, Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors, Liver International, 2014, 34, 10
  17. 17
    Paige M. Porrett, Sohaib K. Hashmi, Abraham Shaked, Immunosuppression, Clinics in Liver Disease, 2014, 18, 3, 687

    CrossRef

  18. 18
    Evangelos Cholongitas, Chrysanthi Mamou, Kryssia I. Rodríguez-Castro, Patrizia Burra, Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review, Transplant International, 2014, 27, 10
  19. 19
    Sonia Schneer, Mordechai R. Kramer, Benjamin Fox, Viktoria Rusanov, Oren Fruchter, Dror Rosengarten, Ilana Bakal, Benjamin Medalion, Yael Raviv, Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant, Clinical Transplantation, 2014, 28, 6
  20. 20
    Sung-Hwa Kang, Shin Hwang, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Gil-Chun Park, Bo-Hyun Jung, Young-In Yoon, Sung-Gyu Lee, Tailored long-term immunosuppressive regimen for adult liver transplant recipients with hepatocellular carcinoma, Korean Journal of Hepato-Biliary-Pancreatic Surgery, 2014, 18, 2, 48

    CrossRef

  21. 21
    Goran B. Klintmalm, Björn Nashan, The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence, Journal of Transplantation, 2014, 2014, 1

    CrossRef

  22. 22
    Lewis Teperman, Dilip Moonka, Anthony Sebastian, Linda Sher, Paul Marotta, Christopher Marsh, Baburao Koneru, John Goss, Dennis Preston, John P. Roberts, Calcineurin Inhibitor–Free Mycophenolate Mofetil/Sirolimus Maintenance in Liver Transplantation: The Randomized Spare-the-Nephron Trial, Liver Transplantation, 2013, 19, 7
  23. 23
    Susanne Beckebaum, Vito R. Cicinnati, Arnold Radtke, Iyad Kabar, Calcineurin inhibitors in liver transplantation – still champions or threatened by serious competitors?, Liver International, 2013, 33, 5
  24. 24
    James F. Trotter, Monica Grafals, Angel E. Alsina, Early use of renal-sparing agents in liver transplantation: A closer look, Liver Transplantation, 2013, 19, 8
  25. 25
    C. Alegre, C. Jiménez, A. Manrique, M. Abradelo, J. Calvo, C. Loinaz, A. García-Sesma, F. Cambra, E. Álvaro, M. García, R. Sanabria, I. Justo, O. Caso, E. Moreno, Everolimus Monotherapy or Combined Therapy in Liver Transplantation: Indications and Results, Transplantation Proceedings, 2013, 45, 5, 1971

    CrossRef

  26. 26
    Gillian M. Keating, Katherine A. Lyseng-Williamson, Everolimus: A Guide to Its Use in Liver Transplantation, BioDrugs, 2013, 27, 4, 407

    CrossRef

  27. 27
    György Gámán, Fanni Gelley, Zsuzsa Gerlei, Eszter Dabasi, Dénes Görög, Imre Fehérvári, László Kóbori, Gabriella Lengyel, Gergely Zádori, János Fazakas, Attila Doros, Enikő Sárváry, Balázs Nemes, Kidney function and liver transplantation, Orvosi Hetilap, 2013, 154, 26, 1018

    CrossRef

  28. 28
    M. Bhat, M. Charlton, Preserving Flow in Liver Transplant Recipients: mTOR Inhibitors Everolimus and Sirolimus Are Not Peas From a Pod, American Journal of Transplantation, 2013, 13, 7
  29. 29
    F. Saliba, P. De Simone, F. Nevens, L. De Carlis, H. J. Metselaar, S. Beckebaum, S. Jonas, D. Sudan, L. Fischer, C. Duvoux, K. D. Chavin, B. Koneru, M. A. Huang, W. C. Chapman, D. Foltys, G. Dong, P. M. Lopez, J. Fung, G. Junge, Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study, American Journal of Transplantation, 2013, 13, 7
  30. 30
    Cheryle Gurk-Turner, Wana Manitpisitkul, Matthew Cooper, A Comprehensive Review of Everolimus Clinical Reports, Transplantation Journal, 2012, 94, 7, 659

    CrossRef

  31. 31
    L. Fischer, J. Klempnauer, S. Beckebaum, H. J. Metselaar, P. Neuhaus, P. Schemmer, U. Settmacher, N. Heyne, P-A. Clavien, F. Muehlbacher, I. Morard, H. Wolters, W. Vogel, T. Becker, M. Sterneck, F. Lehner, C. Klein, G. Kazemier, A. Pascher, J. Schmidt, F. Rauchfuss, A. Schnitzbauer, S. Nadalin, M. Hack, S. Ladenburger, H. J. Schlitt, A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantation—PROTECT, American Journal of Transplantation, 2012, 12, 7
  32. 32
    Nassim Kamar, Chakib Maaroufi, Céline Guilbeau-Frugier, Aude Servais, Vannary Meas-Yedid, Ivan Tack, Eric Thervet, Olivier Cointault, Laure Esposito, Joelle Guitard, Laurence Lavayssière, Clarisse Panterne, Fabrice Muscari, Christophe Bureau, Lionel Rostaing, Do kidney histology lesions predict long-term kidney function after liver transplantation?, Clinical Transplantation, 2012, 26, 6
  33. 33
    Roberto Montalti, Antonio Mimmo, Gianluca Rompianesi, Valentina Serra, Nicola Cautero, Roberto Ballarin, Nicola De Ruvo, Robert Cunningham Gerring, Giorgio Enrico Gerunda, Fabrizio Di Benedetto, Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation, Liver Transplantation, 2012, 18, 2
  34. 34
    T.M. Manzia, D. Sforza, R. Angelico, M.I. Bellini, P. Ciano, M. Manuelli, L. Toti, G. Tisone, Everolimus and Enteric-Coated Mycophenolate Sodium Ab Initio after Liver Transplantation: Midterm Results, Transplantation Proceedings, 2012, 44, 7, 1942

    CrossRef

  35. 35
    Erika Roat, Sara De Biasi, Linda Bertoncelli, Gianluca Rompianesi, Milena Nasi, Lara Gibellini, Marcello Pinti, Cinzia del Giovane, Andrea Zanella, Fabrizio Di Benedetto, Giorgio Enrico Gerunda, Andrea Cossarizza, Immunological advantages of everolimus versus cyclosporin A in liver-transplanted recipients, as revealed by polychromatic flow cytometry, Cytometry Part A, 2012, 81A, 4
  36. 36
    Joachim Andrassy, Verena S. Hoffmann, Markus Rentsch, Manfred Stangl, Antje Habicht, Bruno Meiser, Michael Fischereder, Karl-Walter Jauch, Markus Guba, Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitor–Based Immunosuppression? A Systematic Review and Meta-Analysis, Transplantation Journal, 2012, 94, 12, 1208

    CrossRef

  37. 37
    James Trotter, Ben Kahn, Renal dysfunction and the liver transplant recipient; novel strategies for determination of reversibility and renal protective therapies pretransplant and posttransplant, Current Opinion in Organ Transplantation, 2012, 17, 3, 225

    CrossRef

  38. 38
    Lionel Rostaing, Faouzi Saliba, Yvon Calmus, Sébastien Dharancy, Olivier Boillot, Review article: Use of induction therapy in liver transplantation, Transplantation Reviews, 2012, 26, 4, 246

    CrossRef

  39. 39
    Greg J. McKenna, James F. Trotter, Sirolimus – It doesn’t deserve its bad Rap(a), Journal of Hepatology, 2012, 56, 1, 285

    CrossRef

  40. 40
    Fuat H. Saner, Vito R. Cicinnati, Georgios Sotiropoulos, Susanne Beckebaum, Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation, Liver International, 2012, 32, 2
  41. 41
    T. Pérez, R. Segovia, L. Castro, J.P. Roblero, R. Estela, Conversion to Everolimus in Liver Transplant Patients With Renal Dysfunction, Transplantation Proceedings, 2011, 43, 6, 2307

    CrossRef

  42. 42
    Faouzi Saliba, Sébastien Dharancy, Richard Lorho, Filoména Conti, Sylvie Radenne, Martine Neau-Cransac, Monika Hurtova, Jean Hardwigsen, Yvon Calmus, Jérome Dumortier, Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis, Liver Transplantation, 2011, 17, 8
  43. 43
    Fabrizio Sansone, Mauro Rinaldi, Cyclosporine monotherapy in cardiac transplantation, Transplantation Reviews, 2011, 25, 4, 131

    CrossRef

  44. 44
    Liset H. M. Pengel, Liang Q. Liu, Peter J. Morris, Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials, Transplant International, 2011, 24, 12
  45. 45
    M. Trinidad Serrano Aulló, Eduardo Parra Moncasi, Sara Lorente Pérez, Inmunosupresión en el trasplante hepático: pautas renoprotectoras, Gastroenterología y Hepatología, 2011, 34, 6, 422

    CrossRef

  46. 46
    Toshiyasu Kawahara, Sonal Asthana, Norman M. Kneteman, m-TOR inhibitors: What role in liver transplantation?, Journal of Hepatology, 2011, 55, 6, 1441

    CrossRef

  47. 47
    Dirk Nielsen, Andrea Briem-Richter, Marijke Sornsakrin, Lutz Fischer, Bjoern Nashan, Rainer Ganschow, The use of everolimus in pediatric liver transplant recipients: First experience in a single center, Pediatric Transplantation, 2011, 15, 5
  48. 48
    G. McKenna, J. F. Trotter, Does Early (CNI) Conversion Lead to Eternal (Renal) Salvation?, American Journal of Transplantation, 2010, 10, 10